THAR - MCAP CO - Tharimmune, Inc.

The Tharimmune, Inc. (THAR) ecosystem develops advanced therapies for liver and skin lesions by implementing specific antibodies to alleviate chronic pruritus. The business currently relies on intensive R&D and clinical trials of new immunomodulators. Its technology stack is augmented by AI and robotics to accelerate the selection of anti-tumor compounds. Market capitalization stands at , as confirmed by the price evolution charts provided below.

The development progress of drugs by Tharimmune, Inc. (THAR) to combat autoimmune inflammation is directly reflected in the company's market capitalization. This indicator represents the aggregate market value of all the issuer's outstanding shares. The calculation is performed by multiplying the current quote by the total number of securities in circulation. For a biotech startup sustained by grants, this metric serves as a gauge of market confidence in future research. Growth in this metric confirms the capitalization of the business's intellectual potential.